.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Poster Presentation
P-II-026

Neutralising Antibodies and Avidity to SARS-CoV-2 spike protein in patients undergoing haemodialysis

Termin

Datum: Di, 04.06.2024

Zeit: 17:30 – 17:30

Redezeit: 0 Min.

Diskussionszeit: 0 Min.

Ort / Stream:

Poster Exhibition

Poster

Neutralising Antibodies and Avidity to SARS-CoV-2 spike protein in patients undergoing haemodialysis

Session

Poster Session 2

Thema

Infection Immunology

Mitwirkende

Roswitha Götte (Würzburg / DE), Michael Fladerer (Würzburg / DE), Luca Huth (Würzburg / DE), Lukas Schäfer (Würzburg / DE), Giovanni Almanzar (Würzburg / DE), Torsten Stövesand (Würzburg / DE), Christiane Drechsler (Würzburg / DE), Martina Prelog (Würzburg / DE)

Abstract

Introduction:
Patients undergoing haemodialysis (HD) have been recommended to receive booster doses of mRNA vaccines against SARS-CoV-2 as part of the group of persons at risk for severe sequelae of coronavirus disease (Covid-19).

Question:
The aim of this study was to longitudinally analyse the humoral immune response to spike protein and the impact breakthrough infections (BTI) in HD.

Materials & Methods:
82 HD and 38 healthy controls (HC) had received a total of 3 to 5 mRNA vaccinations. Blood samples were taken before and at 2 and 4 weeks and at 3, 6 and 9 months after vaccination. The concentration anti-spike-IgG (binding antibody units, BAU/ml) and the relative avidity index (%) were assessed by adaption of a commercially available ELISA assay using thiocyanate as chaotropic reagent.

Results:
HD who had received a 5th vaccination 6 months after the 4th vaccination showed a higher anti-spike-IgG (mean 3335,35 BAU/ml) after 6 months compared to HD who had received only 4 vaccinations and were evaluated at time point 12 months after the 4th vaccination (2344,83 BAU/ml). The RAI remained similar between HD who were vaccinated five times and those who had 4 vaccinations (76,64% versus 79,33%) with no significant difference compared to HC (78,08%). HD with BTI in the last 6 months showed 1,57-fold higher anti-spike-IgG compared to those without BTI.

Conclusion:
The results revealed an immunological benefit of a fifth vaccination for HD patients by higher anti-spike-IgG concentrations. Hybrid immunity by BTI was able to further induce anti-spike-IgG. The findings corroborate the recommendation for repeated COVID19 mRNA vaccinations in HD patients.